Evidence map›Paper›PMID 42123691›Full record

ArticleInternational journal of molecular sciences2026

Impact of Pharmacogenetic Markers on the Efficacy of Neoadjuvant FLOT Chemotherapy in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma.

Denis Fedorinov, Vladimir Lyadov, Marina Lyadova, Sherzod Abdullaev, Anastasia Kachanova, Anna Filatova, Dmitriy Ivashchenko, Dmitry Sychev

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Denis FedorinovFederal State Budgetary Research Institution «Russian Research Center of Surgery Named After Academician B.V. Petrovsky», Moscow 119991, Russia.ORCID 0000-0001-5516-7367
Vladimir LyadovFederal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation, Moscow 125993, Russia.ORCID 0000-0002-7281-3591
Marina LyadovaMoscow State Budgetary Healthcare Institution "Oncological Center No. 1 of Moscow City Hospital Named After S.S. Yudin, Moscow Healthcare Department", Moscow 115446, Russia.
Sherzod AbdullaevFederal State Budgetary Research Institution «Russian Research Center of Surgery Named After Academician B.V. Petrovsky», Moscow 119991, Russia.ORCID 0000-0001-9001-1499
Anastasia KachanovaFederal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation, Moscow 125993, Russia.
Anna FilatovaE.M. Tareev Clinic of Rheumatology, Nephrology, and Occupational Pathology. I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia.
Dmitriy IvashchenkoFederal State Budgetary Research Institution «Russian Research Center of Surgery Named After Academician B.V. Petrovsky», Moscow 119991, Russia.ORCID 0000-0002-2295-7167
Dmitry SychevFederal State Budgetary Research Institution «Russian Research Center of Surgery Named After Academician B.V. Petrovsky», Moscow 119991, Russia.ORCID 0000-0002-4496-3680

Funding

Ministry of Science and Higher Education of the Russian Federation 075-15-2025-463
6 · The paper itself

Abstract

Despite the adoption of neoadjuvant FLOT chemotherapy as standard treatment for locally advanced gastric and gastroesophageal junction cancer, many patients fail to achieve meaningful pathological response, limiting efficacy. The aim of this study was to evaluate the impact of pharmacogenetic markers on pathological response in Russian patients receiving neoadjuvant FLOT. Thirty patients with locally advanced gastric or gastroesophageal junction adenocarcinoma received neoadjuvant FLOT followed by surgery. Polymorphisms in

Indexed as

AdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsEsophagogastric JunctionStomach NeoplasmsAdultAgedBiomarkers, TumorDNA-Binding ProteinsEndonucleasesFemaleGlutathione S-Transferase piHumansMaleMiddle AgedNeoadjuvant TherapyBiomarkers, TumorDNA-Binding ProteinsEndonucleasesERCC1 protein, humanGlutathione S-Transferase piGSTP1 protein, humancancerERCC1genegeneticsgenomegenotypepharmacogeneticspharmacogenomics

Identifiers

PMID42123691
PMCPMC13164360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.